-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60

Benzinga·09/18/2026 11:14:25
Listen to the news
Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and lowers the price target from $78 to $60.